- call +1-201-465-4211
- email sales@mrinsights.biz
Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness.
Scope of the Report:
Of the five key indications within the therapy area - glaucoma, AMD, DME, DR and DES - glaucoma and AMD have the most active product pipelines.
The global Ophthalmology Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Ophthalmology Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Ophthalmology Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Ophthalmology Drugs market by product type and applications/end industries.
Market Segment by Companies, this report covers
Novartis
Regeneron
Roche
Bayer
Allergan
Shire
Mallinckrodt
Santen Pharmaceutical
Aerie
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Lucentis (Ranibizumab)
Eylea (Aflibercept)
Avastin (Bevacizumab)
Restasis (Cyclosporine)
Alphagan (Brimonidine Tartrate)
Lumigan (Bimatoprost)
Xalatan (Latanoprost)
Conclusion
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Ophthalmology Drugs Market Overview
1.1 Product Overview and Scope of Ophthalmology Drugs
1.2 Classification of Ophthalmology Drugs by Types
1.2.1 Global Ophthalmology Drugs Revenue Comparison by Types (2017-2023)
1.2.2 Global Ophthalmology Drugs Revenue Market Share by Types in 2017
1.2.3 Lucentis (Ranibizumab)
1.2.4 Eylea (Aflibercept)
1.2.5 Avastin (Bevacizumab)
1.2.6 Restasis (Cyclosporine)
1.2.7 Alphagan (Brimonidine Tartrate)
1.2.8 Lumigan (Bimatoprost)
1.2.9 Xalatan (Latanoprost)
1.2.10 Conclusion
1.3 Global Ophthalmology Drugs Market by Application
1.3.1 Global Ophthalmology Drugs Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Drug Stores
1.3.5 Online Sales
1.4 Global Ophthalmology Drugs Market by Regions
1.4.1 Global Ophthalmology Drugs Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Ophthalmology Drugs Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Ophthalmology Drugs Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Ophthalmology Drugs Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Ophthalmology Drugs Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Ophthalmology Drugs Status and Prospect (2013-2023)
1.5 Global Market Size of Ophthalmology Drugs (2013-2023)
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Business Overview
2.1.2 Ophthalmology Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Novartis Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.2 Regeneron
2.2.1 Business Overview
2.2.2 Ophthalmology Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Regeneron Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.3 Roche
2.3.1 Business Overview
2.3.2 Ophthalmology Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Roche Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bayer
2.4.1 Business Overview
2.4.2 Ophthalmology Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bayer Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.5 Allergan
2.5.1 Business Overview
2.5.2 Ophthalmology Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Allergan Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.6 Shire
2.6.1 Business Overview
2.6.2 Ophthalmology Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Shire Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.7 Mallinckrodt
2.7.1 Business Overview
2.7.2 Ophthalmology Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Mallinckrodt Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.8 Santen Pharmaceutical
2.8.1 Business Overview
2.8.2 Ophthalmology Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Santen Pharmaceutical Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.9 Aerie
2.9.1 Business Overview
2.9.2 Ophthalmology Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Aerie Ophthalmology Drugs Revenue, Gross Margin and Market Share (2016-2017)
3 Global Ophthalmology Drugs Market Competition, by Players
3.1 Global Ophthalmology Drugs Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Ophthalmology Drugs Players Market Share
3.2.2 Top 10 Ophthalmology Drugs Players Market Share
3.3 Market Competition Trend
4 Global Ophthalmology Drugs Market Size by Regions
4.1 Global Ophthalmology Drugs Revenue and Market Share by Regions
4.2 North America Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
4.3 Europe Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
4.5 South America Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
5 North America Ophthalmology Drugs Revenue by Countries
5.1 North America Ophthalmology Drugs Revenue by Countries (2013-2018)
5.2 USA Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
5.3 Canada Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
5.4 Mexico Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
6 Europe Ophthalmology Drugs Revenue by Countries
6.1 Europe Ophthalmology Drugs Revenue by Countries (2013-2018)
6.2 Germany Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
6.3 UK Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
6.4 France Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
6.5 Russia Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
6.6 Italy Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Ophthalmology Drugs Revenue by Countries
7.1 Asia-Pacific Ophthalmology Drugs Revenue by Countries (2013-2018)
7.2 China Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
7.3 Japan Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
7.4 Korea Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
7.5 India Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
8 South America Ophthalmology Drugs Revenue by Countries
8.1 South America Ophthalmology Drugs Revenue by Countries (2013-2018)
8.2 Brazil Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
8.3 Argentina Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
8.4 Colombia Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Ophthalmology Drugs by Countries
9.1 Middle East and Africa Ophthalmology Drugs Revenue by Countries (2013-2018)
9.2 Saudi Arabia Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
9.3 UAE Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
9.4 Egypt Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
9.5 Nigeria Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
9.6 South Africa Ophthalmology Drugs Revenue and Growth Rate (2013-2018)
10 Global Ophthalmology Drugs Market Segment by Type
10.1 Global Ophthalmology Drugs Revenue and Market Share by Type (2013-2018)
10.2 Global Ophthalmology Drugs Market Forecast by Type (2018-2023)
10.3 Lucentis (Ranibizumab) Revenue Growth Rate (2013-2023)
10.4 Eylea (Aflibercept) Revenue Growth Rate (2013-2023)
10.5 Avastin (Bevacizumab) Revenue Growth Rate (2013-2023)
10.6 Restasis (Cyclosporine) Revenue Growth Rate (2013-2023)
10.7 Alphagan (Brimonidine Tartrate) Revenue Growth Rate (2013-2023)
10.8 Lumigan (Bimatoprost) Revenue Growth Rate (2013-2023)
10.9 Xalatan (Latanoprost) Revenue Growth Rate (2013-2023)
10.10 Conclusion Revenue Growth Rate (2013-2023)
11 Global Ophthalmology Drugs Market Segment by Application
11.1 Global Ophthalmology Drugs Revenue Market Share by Application (2013-2018)
11.2 Ophthalmology Drugs Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacies Revenue Growth (2013-2018)
11.4 Retail Pharmacies Revenue Growth (2013-2018)
11.5 Drug Stores Revenue Growth (2013-2018)
11.6 Online Sales Revenue Growth (2013-2018)
12 Global Ophthalmology Drugs Market Size Forecast (2018-2023)
12.1 Global Ophthalmology Drugs Market Size Forecast (2018-2023)
12.2 Global Ophthalmology Drugs Market Forecast by Regions (2018-2023)
12.3 North America Ophthalmology Drugs Revenue Market Forecast (2018-2023)
12.4 Europe Ophthalmology Drugs Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Ophthalmology Drugs Revenue Market Forecast (2018-2023)
12.6 South America Ophthalmology Drugs Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Ophthalmology Drugs Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Ophthalmology Drugs Picture
Table Product Specifications of Ophthalmology Drugs
Table Global Ophthalmology Drugs and Revenue (Million USD) Market Split by Product Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
